Comprehensive Analysis of RAPGEF2 for Predicting Prognosis and Immunotherapy Response in Patients with Hepatocellular Carcinoma

Qing Wu; Yangzhi Hu; Qinghui Ma; Shanglin Yang; Junpeng Chen; Shunqian Wen; Guanqun Liao

doi:10.1155/2022/6560154

Comprehensive Analysis of RAPGEF2 for Predicting Prognosis and Immunotherapy Response in Patients with Hepatocellular Carcinoma

J Oncol. 2022 Apr 26:2022:6560154. doi: 10.1155/2022/6560154. eCollection 2022.

Authors

Qing Wu¹, Yangzhi Hu², Qinghui Ma³, Shanglin Yang¹, Junpeng Chen¹, Shunqian Wen¹, Guanqun Liao¹

Affiliations

¹ Department of Hepatobiliary Surgery, Affiliated Foshan Hospital, Southern Medical University (The Second People's Hospital of Foshan), Foshan 528000, China.
² Department of Gastrointestinal Surgery, The Affiliated Hospital of Xiangnan University, Chenzhou 423000, China.
³ Department of Oncology, Affiliated Foshan Hospital, Southern Medical University (The Second People's Hospital of Foshan), Foshan 528000, China.

Abstract

Background: Hepatocellular carcinoma (HCC) is the sixth most common tumor worldwide. Additionally, deletion of RAPGEF2 plays a critical role in CNV and related to tumor immune microenvironment, whereas the prognostic potential of RAPGEF2 in HCC patient needs to be explored.

Methods: We looked for prognostic potential genes in HCC using a variety of R programs. Then, using the LASSO Cox regression, we thoroughly evaluated and integrated the RAPGEF2-related genes from TCGA database. Meanwhile, utilizing TCGA and ICGA databases, the link between RAPGEF2 and immunotherapy response in HCC was studied. In vivo, the effect of RAPGEF2 on tumor development and the capacity of natural killer (NK) cells to recruit were confirmed. To ascertain the connection between RAPGEF2-related genes and the prognosis of HCC, a prognostic model was created and validated.

Result: We demonstrated RAPGEF2 has a differential expression, and patients with deletion of RAPGEF2 gene get shorter survival in HCC. Additionally, the tissues without RAPGEF2 have a weaker ability to recruit the NK cells and response to immunotherapy. After that, we scoured the database for eight RAPGEF2-related genes linked with a better prognosis in HCC patients. Additionally, silencing RAPGEF2 accelerated tumor development in the HCC mouse model and decreased CD56+ NK cell recruitment in HCC tissues. TCGA database was used to classify patients into low- and high-risk categories based on the expression of related genes. Patients in the low-risk group had a significantly greater overall survival than those in the high-risk group (P < 0.001). Meanwhile, the low-risk group demonstrated connections with the NK cell and immunotherapy response. Finally, the prognostic nomogram showed a high sensitivity and specificity for predicting the survival of HCC patients at 1, 2, and 3 years.

Conclusion: The prognostic model based on RAPGEF2 and RAPGEF2-related genes showed an excellent predictive performance in terms of prognosis and immunotherapy response in HCC, therefore establishing a unique prognostic model for clinical assessment of HCC patients.